Global Metastatic Castrate Resistant Prostate Cancer Treatment Market – Industry Trends and Forecast to 2029

Global Metastatic Castrate Resistant Prostate Cancer Treatment Market, By Treatment (Hormone therapies, Xofigo, Sipuleucel-T, Cabazitaxel, Docetaxel, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Market Analysis and Size                              

According to a study published in Cancer Epidemiology 2020, the prevalence and incidence of metastatic castration-resistant prostate cancer (mCRPC) in France are 62 and 21 cases per 100,000 people. Furthermore, men aged 80-89 years old had the highest metastatic castration-resistant prostate cancer (mCRPC) incidence. CRPC is a kind of advanced prostate cancer that is resistant to testosterone-lowering therapy. Difficulty urinating, pain while passing urine, blood in the urine, weight loss, and shortness of breath are all symptoms of mCRPC.

Data Bridge Market Research analyses that the metastatic castrate resistant prostate cancer treatment market was valued at USD 9.50 billion in 2021 and is expected to reach USD 17.71 billion by 2029, registering a CAGR of 8.10% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Metastatic castrate resistant prostate cancer is a type of prostate cancer that has spread to other places of the body or has failed to respond to treatment. It's estimated that 10 to 15% of prostate cancer patients are castrate-resistant metastatic prostate cancer. Hormone therapies, xofigo, sipuleucel-T, cabazitaxel, and docetaxel are the new options for the treatment of metastatic castrate resistant prostate cancer. Androgen deprivation therapy (ADT), also known as hormone therapy, dramatically lowers testosterone levels in the body. The testosterone levels have been decreased to the point that they are comparable to males who have had their testicles surgically removed. Some of the potential treatments for castrate-resistant prostate cancer include alternative hormonal medicines such as Abiraterone (Zytiga) and Enzalutamide (Xtandi), immunotherapy and chemotherapy.

Metastatic Castrate Resistant Prostate Cancer Treatment Market Dynamics

Drivers

• Increasing prevalence of metastatic prostate cancers

The rising prevalence of metastatic prostate cancers is anticipated to drive the metastatic castrate resistant prostate cancer treatment market's growth. According to the National Cancer Institute, prostate cancer is the sixth greatest cause of cancer death in the United States. The annual incidence of new prostate cancer cases was 109.8 per 100,000 men. In 2017, an estimated 3,170,339 males in the United States were diagnosed with prostate cancer. It is anticipated that 191,930 new cases of prostate cancer would be diagnosed in 2020. According to the World Health Organization, approximately 1.41 million men were diagnosed with prostate cancer in 2020.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of metastatic castrate resistant prostate cancer treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, surging geriatric population and unhealthy lifestyle of people will result in the expansion of metastatic castrate resistant prostate cancer treatment market. Along with this, favourable reimbursement policies and a rising number of government initiatives to spread cancer awareness will enhance the market's growth rate.

Opportunities

• Rising number of clinical trials

Over the forecast period, the worldwide castrate-resistant prostate cancer market is expected to develop due to an increase in the number of clinical trials to treat castrate-resistant prostate cancer. This is anticipated to boost the new market opportunities. For instance, at the American Society of Clinical Oncology's Genitourinary (ASCO GU) Cancers Symposium on February 8, 2021, Janssen Pharmaceutical NV, a Johnson & Johnson subsidiary, presented findings from the Phase 3 ACIS Study in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with a combination of ERLEADA (apalutamide) and ZYTIGA (abiraterone acetate). The primary purpose of the ACIS research was to reduce the time between radiographic progression and death in individuals with mCRPC.

Moreover, the market's growth is fueled by an increase in the number of research and development activities and emerging new markets. These factors will provide beneficial opportunities for the metastatic castrate resistant prostate cancer treatment market growth.

Restraints/Challenges

• High cost associated with the treatment

The high cost associated with the treatment will obstruct the growth rate of market. As per the American Cancer Society, prostate cancer costs on average USD 4,300 up front and USD 9,100 over five years, with surgery costing USD 15,000 upfront and USD 19,000 over five years. Hormone therapy with radiation costs USD 17,500 up front and USD 25,000 over five years. Costs for patients with advanced or metastatic prostate cancer might exceed USD 100,000.

On the other hand, the lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the metastatic castrate resistant prostate cancer treatment market. Additionally, lack of awareness among people and unfavorable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This metastatic castrate resistant prostate cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the metastatic castrate resistant prostate cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Metastatic castrate resistant prostate cancer treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Metastatic Castrate Resistant Prostate Cancer Treatment Market

The metastatic castrate resistant prostate cancer treatment market was seen to be down due to hurdles in the production and sales divisions as a result of the COVID-19 outbreak. Since the pandemic, all manufacturers have been shut down save for masks, sanitizers, and ventilators. As a result, fewer drugs were manufactured during the outbreak than in prior years. On the other hand, clinical studies were disrupted during this time and have yet to fully recover in the post-lockdown period. In the worst-case situation, it could have an impact on future demand for global metastatic prostate cancer therapy.

Recent Development

• In March 2022, Novartis had announced the U.S. Food and Drug Administration (FDA) approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617). It is used for treating adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) which has spread to various parts of the body (metastatic)1. Pluvicto is the first FDA-approved targeted radioligand therapy (RLT) that combines a targeting chemical (ligand) with a therapeutic radioisotope for eligible individuals with mCRPC (a radioactive particle). Pluvicto should be available to doctors and patients in a few weeks.

Global Metastatic Castrate Resistant Prostate Cancer Treatment Market Scope

The metastatic castrate resistant prostate cancer treatment market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Hormone therapies

Enzalutamide

Abiraterone

• Xofigo
• Sipuleucel-T
• Cabazitaxel
• Docetaxel
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Metastatic Castrate Resistant Prostate Cancer Treatment Market Regional Analysis/Insights

The metastatic castrate resistant prostate cancer treatment market is analysed and market size insights and trends are provided by country, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the metastatic castrate resistant prostate cancer treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the metastatic castrate resistant prostate cancer treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence cases of prostate cancer and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the growing focus of major key players on novel technology will further propel themarket's growth rate in this region.

Europe is expected to be the fastest growing region during the forecast period of 2022-2029 due to high diagnosis rate in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Metastatic Castrate Resistant Prostate Cancer Treatment Market Share Analysis

The metastatic castrate resistant prostate cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to metastatic castrate resistant prostate cancer treatment market.

Some of the major players operating in the metastatic castrate resistant prostate cancer treatment market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• AbbVie Inc. (U.S.)
• WOCKHARDT (Mumbai)
• Johnson & Johnson Private Limited (U.S.)
• Cipla Inc. (U.S.)  
• Amneal Pharmaceuticals LLC. (U.S.)
• Eisai Co., Ltd. (Japan)
• Bausch Health Companies Inc. (Canada)
• Abbott (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Merck KGaA (Germany)